Announcements Trials

Browse Landscape

Phase

Status

Unknown 5 Recruiting 3 Withdrawn 1 Terminated 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 2 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Solid Tumors 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Mesothelioma, Malignant 1 Leukemia, Myeloid, Acute 1 Head and Neck Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Anus Neoplasms 1

Interventions

pembrolizumab 9 Paclitaxel 9 Doxorubicin 6 Cyclophosphamide 6 Carboplatin 5 130-nm albumin-bound paclitaxel 5 durvalumab 3 yeast-CEA vaccine 2 talazoparib 2 sacituzumab govitecan 2 olaparib 2 glembatumumab vedotin 2 avelumab 2 Taxes 2 Radiotherapy 2 Leucovorin 2 Fluorouracil 2 Cisplatin 2 Capecitabine 2 Biopsy 2 Albumin-Bound Paclitaxel 2 ALT-803 2 zimberelimab 1 trifluridine tipiracil drug combination 1 tremelimumab 1 trastuzumab duocarmazine 1 tislelizumab 1 taxane 1 sabizabulin 1 poly ICLC 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Triple Negative Breast Neoplasms × tislelizumab × Clear all

NCT05809895 2023-07-24

AdvanTIG-211

Novartis

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡